The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Diurnal Group plc

16 Sep 2022 08:53

RNS Number : 7414Z
Panmure Gordon (UK) Limited
16 September 2022
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Diurnal Group PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Diurnal Group PLC

(d) Date dealing undertaken:

15 Sep 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

10p Ordinary

Purchase

 

27,994

0.267

 

0.267

 

10p Ordinary

Sales

190,873

0.269

 

0.2682

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

16/09/2022

Contact name:

Mohammed Jamal

Telephone number:

020 7886 2780

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERDZGMLNVLGZZG
Date   Source Headline
30th Apr 20193:40 pmRNSHolding(s) in Company
30th Apr 20192:43 pmRNSHolding(s) in Company
26th Apr 20195:52 pmRNSDirector Dealings and Issue of Equity
26th Apr 20193:10 pmRNSHolding(s) in Company
25th Apr 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway
24th Apr 20197:00 amRNSGrant of Orphan Drug Designation in Australia
11th Apr 20197:00 amRNSPositive Scientific Advice from EMA for Chronocort
28th Mar 20197:00 amRNSDiurnal signs marketing and distribution agreement
28th Mar 20197:00 amRNSInterim Results
20th Mar 20197:00 amRNSUpdate on Alkindi US development
25th Feb 20197:00 amRNSSubmission of MAA for Alkindi and Second Patent
11th Feb 201911:00 amRNSNotice of Interim Results
17th Jan 20197:00 amRNSDirector Dealings
16th Jan 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice
10th Jan 201912:18 pmRNSStatement regarding Price Movement
10th Jan 20197:00 amRNSGrant of second US patent for Chronocort
24th Dec 20187:00 amRNSDirector Dealings and Issue of Equity
12th Dec 20184:02 pmRNSDirector Dealings
11th Dec 20187:00 amRNSRegulatory package for Scientific Advice in Europe
4th Dec 20181:08 pmRNSDirector/PDMR Shareholding
14th Nov 201811:38 amRNSResults of Annual General Meeting
14th Nov 201810:16 amRNSIssue of Equity and Exercise of Options
18th Oct 20187:15 amEQSHardman & Co Research: Diurnal Group (DNL): Unexpected Phase III trial outcome
17th Oct 20187:00 amRNSUpdate on late-stage development pipeline
8th Oct 20184:00 pmRNSPosting of Annual Report and AGM Notice
8th Oct 20182:45 pmRNSSMC Approves The Use of Alkindi
8th Oct 20187:00 amRNSHeadline Data for Chronocort European Phase III
5th Oct 20187:00 amRNSFirst patients enrolled in US Chronocort Phase III
20th Sep 20187:00 amRNSResults for the year ended 30 June 2018
15th Aug 201811:11 amRNSUpdate on Alkindi® in Germany
10th Jul 20181:36 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSNotice of Results
18th Jun 20184:54 pmRNSDirector/PDMR Shareholding
18th May 20183:33 pmRNSDirector Dealings
18th May 20181:11 pmRNSAppointment of NOMAD and Joint Broker
15th May 20188:13 amRNSLaunch of Alkindi for paediatric AI in Germany
11th May 20182:41 pmRNSDirector Declaration
17th Apr 20183:58 pmRNSHolding(s) in Company
5th Apr 20182:08 pmRNSDirector/PDMR Shareholding
5th Apr 20188:01 amRNSDirector/PDMR Shareholding
3rd Apr 20182:39 pmRNSResult of GM and Completion of £10.5m Placing
21st Mar 20187:15 amRNSHardman & Co: New capital funds commercial plans
20th Mar 20185:20 pmRNSPlacing Update
14th Mar 20188:47 amRNSProposed Placing
12th Mar 20187:00 amRNSAppointment of CRO to support US Chronocort trials
12th Mar 20187:00 amRNSHalf-year Report
22nd Feb 20187:00 amRNSDiurnal announces grant of first patents in Japan
19th Feb 20187:00 amRNSCommercialisation agreement in Australia and NZ
13th Feb 20187:00 amRNSEuropean marketing authorisation for Alkindi®
12th Feb 20187:00 amRNSCompletion of patient enrolment in EU Phase III

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.